Treatment of HAE Attacks in the Icatibant Outcome Survey: An Analysis of Icatibant Self-Administration versus Administration by Health Care Professionals.

@article{Rojas2015TreatmentOH,
  title={Treatment of HAE Attacks in the Icatibant Outcome Survey: An Analysis of Icatibant Self-Administration versus Administration by Health Care Professionals.},
  author={Dolores Hern{\'a}ndez Fern{\'a}ndez de Rojas and Ethel Iba{\~n}ez and Hilary Longhurst and Marcus Maurer and Vincent Fabien and Werner Aberer and Laurence Bouillet and Andrea Zanichelli and T Caballero},
  journal={International archives of allergy and immunology},
  year={2015},
  volume={167 1},
  pages={21-8}
}
BACKGROUND Icatibant, a selective bradykinin B2 receptor antagonist for the treatment of acute hereditary angio-oedema (HAE) attacks in adults, can be administered by health care professionals (HCPs) or self-administered. This analysis compared characteristics and outcomes of acute HAE attacks treated with self-administered and HCP-administered icatibant in a real-world setting. METHODS The Icatibant Outcome Survey (Shire, Zug, Switzerland; NCT01034969) is an international observational study… CONTINUE READING